50 results
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
of bulk drug substances and the formulation, testing and packaging of preclinical and clinical drug supplies of our product candidates
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
to control the supply, manufacture and testing of bulk drug substances and the formulation, testing and packaging of preclinical and clinical drug supplies
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale
8-K
EX-10.1
lgpdu7ku
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
EX-10.1
jf8 q0g1zdzq6
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
8-K/A
EX-10.1
nwdzckgogj6nzwjdk
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
kg8cwvcs gev7zw5q
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
8-K
EX-1.1
ogstuqv 1u
11 Mar 21
Entry into a Material Definitive Agreement
8:34am
424B3
lpc3qaj
2 Oct 20
Prospectus supplement
9:25am
S-4/A
5szf2 ofczc2924yc
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
S-4
hlml4la2estoi5l
6 Jul 20
Registration of securities issued in business combination transactions
4:08pm
8-K
EX-10.1
wfs5vhm2wxvgbf
1 Jul 20
Entry into a Material Definitive Agreement
8:37am
425
EX-10.1
yzclnm c79r6r
1 Jul 20
Business combination disclosure
8:35am